Marizyme, Inc.'s Krillase Therapeutic Platform Shows Wide Medical Application and Treatment Potential -- Spotlight Growth

3/14/2019, 2:00 PM (Source: GlobeNewswire)

Sacramento, CA, March 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Spotlight Growth has published new content on Marizyme, Inc. (“Marizyme” or the “Company”) (OTC Pink: MRZM), a biotechnology company focused on its clinically-tested and patented use of protease therapeutic platform called Krillase. Clinical testing and research have shown Krillase to be a treatment for acute ischemic stroke, myocardial infarction, deep-vein thrombosis, wound/burn care, and more. Krillase is classified as a Class III medical device in Europe for the treatment of chronic wounds.

The comprehensive report provides an overview of Marizyme, the Krillase platform, latest news, and management’s plans to continue growing the company. 

ResearchAndMarkets: Global Wound Care Market Estimated Worth $42.07 Billion By 2024

The global population continues to age, as fewer people continue to have children. According to the World Bank, the global population aged 65 or older has grown from 4.97% in 1960 to an estimated 8.70% in 2017. Aside from the aging population, global society suffers from poor diet and increasingly sedentary lifestyles. This has led to a worldwide increase in diseases such as diabetes and obesity. These factors present a number of challenges for society, particularly healthcare services and technology to meet growing demand for care. 

Wound care is another key market that will be in focus due to aging populations and diseases facing the globe today. Chronic wound care is already a multi-billion-dollar market and is forecast to see continue growth.

According to, the global wound care market is estimated to grow to $42.07 billion by 2024, which represents a CAGR of 6.20% between 2018 and 2024. The market research firm notes that an increasingly aged population, growth in surgeries, and even increasing road accidents as major sources of growth for the wound care market. sees the United States as being one of the main drivers of growth, but the market researchers also see strength from other parts of the world. 

Global Market Insights, Inc. estimates the global advanced wound care market to reach $13 billion by 2024, which represents a CAGR of 5.40%. The market research analysts estimate that North America will continue to dominate the market through 2024. With that said, other international markets are estimated to see faster growth over the same time period.

According to the report, “Rising incidences chronic diseases and consequent rise in number of patients with acute and chronic wounds will escalate the market growth over forecast timeframe. Favorable demographic trends such as increasing geriatric population and lifestyle changes such as adoption of sedentary lifestyle will further support rise in prevalence of chronic diseases. This is expected to escalate the prevalence of wounds and associated cost burden thereby augmenting demand for wound care products.” 

MRZM: Initial Krillase Application To Focus On Wound Care and Thrombosis Markets

Marizyme, Inc.’s Krillase main active ingredient can only be derived from Antarctic krill. The mix of proteinases and peptidases helps the Antarctic krill digest and break down its food in the extremely cold environment. As a result, the specialized enzymes provide a “cutting” capability. Krillase has already been classified as a Class III medical device in Europe for the treatment of chronic wounds. 

Currently, Marizyme has a product pipeline that seeks to focus on developing products that treat the most expensive conditions across the acute care market. Here is a breakdown of the breakdown of the current pipeline and where it stands in the clinical stages

·      MB101 – Therapy for Complex Infected Wounds & Burns: Completed Phase 1 trials

·      MB102 – Therapy for Acute Ischemic Stroke: Nearing end of pre-clinical stage

·      MB103 – Therapy for Ischemic Myocardial Infarcs: Halfway through pre-clinical stage

·      MB104 – Therapy for Deep Vein Thrombosis: Early pre-clinical stage

While these represent the first four focuses that Marizyme will turn to, the company also plans to obtain additional funds over the next five years to conduct necessary research, development, and clinical testing on the Krillase platform to be a potential treatment in the following markets:

-HIV/AIDS treatment: $20.45 billion market

-Herpes treatment: $1.8 billion market

-Oral mucositis treatment: $1 billion market

-Plaque removal: $500 million market 

-Canker sore treatment: $400 million market

-Gingivitis treatment: $290.50 million market

For more information on Marizyme, please visit: and is a digital hub for micro-caps, small-caps, venture capital, private equity, crowdfunding, cryptocurrency, and other emerging growth investors. serves as our media subsidiary and provides insights on small cap companies.


Spotlight Growth is compensated, either directly or via a third party, to provide investor relations services for its clients. Spotlight Growth creates exposure for companies through a customized marketing strategy, including design of promotional material, the drafting and editing of press releases and media placement.

All information on featured companies is provided by the companies profiled, or is available from public sources. Spotlight Growth and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on external sources that Spotlight Growth believes to be reliable, but its accuracy is not guaranteed. Spotlight Growth may create reports and content that has been compensated by a company or third-parties, or for purposes of self-marketing. Spotlight Growth was compensated two thousand five hundred dollars cash by a third party for the creation and dissemination of this content.

This material does not represent an investment solicitation. Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management.

The above communication, the attachments and external Internet links provided are intended for informational purposes only and are not to be interpreted by the recipient as a solicitation to participate in securities offerings.  Investments referenced may not be suitable for all investors and may not be permissible in certain jurisdictions.

Spotlight Growth and its affiliates, officers, directors, and employees may have bought or sold or may buy or sell shares in the companies discussed herein, which may be acquired prior, during or after the publication of these marketing materials. Spotlight Growth, its affiliates, officers, directors, and employees may sell the stock of said companies at any time and may profit in the event those shares rise in value. For more information on our disclosures, please visit:

Matt Rego

Spotlight Growth.jpg

Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.